Covidien Pure-Play: Pharma Spinoff In The Works

By David Filmore / Email the Author / “The Gray Sheet” Dec. 19, 2011, Vol. 37, No. 51
Business / Word Count: 1016 / Article # 01111219022

Executive Summary

Covidien says it has been working for several years toward separating out its pharma business from its larger and more profitable devices/supplies division.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 1016-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Covidien Pure-Play: Pharma Spinoff In The Works

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Gray Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Covidien Pure-Play: Pharma Spinoff In The Works

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 5

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article